TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it is reaffirming its confidence in the results of the ongoing unblinding of the BiovaxID™ pivotal Phase 3 results. Yesterday, Genitope Corporation announced that its recombinant partial copy of the tumor specific antigen for non-Hodgkins lymphoma, MyVax®, elicited an immune response in just 40% of patients and that its Phase 3 clinical study of MyVax failed to meets its primary endpoint of statistically significant progression free survival vs control group.
